Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Aug 22, 2025

Accession no.: 0001870913-25-000008
Filed: Aug 22, 2025
Trade date: Aug 20-21, 2025
Filing delay: 2 days
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $9.04M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Shanmugam MuthusamyCIK 0001870913	Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Aug 20, 2025	Common Stock	SSaleDisposed	−47,012	$90.27^F1	−$4,243,773.24	484,908	Indirect
Aug 21, 2025	Common Stock	SSaleDisposed	−52,988	$90.44^F3	−$4,792,234.72	431,920	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The shares were sold in multiple trades at prices ranging from $89.21 to $90.83. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

The shares were sold in multiple trades at prices ranging from $89.90 to $91.44. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)